Satellite Symposium 1 |
|
Future insight for the management of pancreatic and biliary tract cancers | |
|
Satellite Symposium 2 |
|
The current and future challenges: Good luck does not always repeat | |
|
Satellite Symposium 3 |
|
The beginning of immunotherapy journey in breast cancer | |
|
Satellite Symposium 4 |
|
Lenvatinib treatment in first line uHCC and subsequent treatments | |
|
Satellite Symposium 5 |
|
Importance of bone health management in palliative setting | |
|
Satellite Symposium 6 |
|
Changing lives with breakthrough cancer pain management | |
|
Satellite Symposium 7 |
|
What is being considered for continuum of care in metastatic colorectal cancer? | |
|
Satellite Symposium 8 |
|
Broaden horizon of new PD-L1 inhibitor, Avelumab | |
Broaden horizon of new PD-L1 inhibitor, Avelumab |
Satellite Symposium 9 |
|
New perspectives for treatment naïve patients with EGFR+ NSCLC | |
|
Satellite Symposium 10 |
|
Continuing Advances in metastatic Breast Cancer: How to make optimal treatment decision for metastatic breast cancer patients | |
|
Satellite Symposium 11 |
|
Treatment options for patients with ALK+ NSCLC: How is the paradigm changing? | |
|
Satellite Symposium 12 |
|
Ever forward with cancer immunotherapy: the progress so far and new frontiers | |
|
Satellite Symposium 13 |
|
From concept to practice - new era of precision medicine | |
Larotrecitinb, “The REAL DRUG” for TRK fusion cancer patients |
Satellite Symposium 14 |
|
Building confidence in Biosimilars: From data to patient |